Ras-related C3 botulinum toxin substrate 1b (Rac1b)

Ras-related C3 botulinum toxin substrate 1b (Rac1b) is an alternatively spliced isoform of the small GTPase Rac1, characterized by the inclusion of a 19-amino acid insertion encoded by exon 3b (UniProt, NIH). This structural modification results in a protein that is constitutively active due to an accelerated GDP/GTP exchange rate and a significantly reduced intrinsic GTPase activity (MDPI, NIH). Rac1b is predominantly expressed in various cancers, including colorectal, breast, and lung carcinomas, where it promotes cell survival, proliferation, and epithelial-mesenchymal transition (EMT) (NIH, ResearchGate). It plays a critical role in mediating resistance to targeted therapies like cetuximab and chemotherapeutic agents such as oxaliplatin and doxorubicin (NIH, ResearchGate). Interestingly, its function is context-dependent; while it is pro-tumorigenic in many tissues, it has been shown to act as a tumor suppressor in pancreatic cancer by antagonizing TGF-beta-induced EMT (NIH, MDPI). Therapeutic targeting of Rac1b involves small molecule inhibitors that block its activation or downstream signaling, as well as agents like ibuprofen that interfere with its alternative splicing (NIH). However, the high sequence similarity between Rac1b and the ubiquitous Rac1 isoform poses a significant challenge for selective drug development (NIH). Monitoring Rac1b expression levels and associated mutations, such as BRAF V600E, serves as a potential strategy for patient stratification and prognosis (NIH, MDPI).

Other names

Rac1bRac1 isoform bRac1 splicing variantRas-related C3 botulinum toxin substrate 1 isoform 2

Inhibition of alternative splicing, inhibition of guanine nucleotide exchange factor (GEF) interaction, inhibition of GTP binding, and direct inhibition of GTPase activity.